Novel immunotherapeutic approaches and targeted drug candidates show promise across several cancer types. Researchers are engineering CAR T cells with endogenous promoter control to selectively deliver immune modulators within tumors, enhancing efficacy in solid cancers. Pancreatic cancer studies highlight EMP1 as a driver of progression and prognosis, providing new therapeutic insights. Additionally, novel inhibitors including YAP1/TEAD disruptors and PTK7-targeted alpha therapies advance in preclinical development, offering hope against pancreatic and ovarian cancers. Advances in spatial multiomics enable detailed mapping of tumor microenvironments critical for personalized therapies.